页 1 从 242 结果
BACKGROUND
Cancer is a group of diseases characterized by aberrant control of cell growth. The annual incidence of cancer is estimated to be in excess of 1.3 million in the United States alone. While surgery, radiation, chemotherapy, and hormones are used to treat cancer, it remains the second
BACKGROUND OF THE INVENTION
Glutamine supplementation has been shown to prevent induction of mammary (breast) cancer in rats by the carcinogen 7,12-dimenthyl-benz[a]anthracene (DMBA) (Feng, Z., et al., Surgical Forum 47:524 526 (1996)). It has also been shown to enhance the effectiveness of
BACKGROUND OF THE INVENTION
Glutamine supplementation has been shown to prevent induction of mammary (breast) cancer in rats by the carcinogen 7,12-dimenthyl-benz[a]anthracene (DMBA) (Feng, Z., et al., Surgical Forum 47:524-526 (1996)). It has also been shown to enhance the effectiveness of
BACKGROUND OF THE INVENTION
Glutamine supplementation has been shown to prevent induction of mammary (breast) cancer in rats by the carcinogen 7,12-dimenthyl-benz[a]anthracene (DMBA) (Feng, Z., et al., Surgical Forum 47:524-526 (1996)). It has also been shown to enhance the effectiveness of
BACKGROUND OF THE INVENTION
Breast cancer is the most frequently diagnosed cancer and the second most common cause of cancer death in women. While endocrine therapies have proven to be initially effective, almost half of breast cancer patients eventually present recurrent tumors that are resistant
Tissue specific adenovirus vectors target breast cancer cells with genes that encode products that kill the cells.
Despite important advances in early detection and treatment, breast cancer remains a major cause of death, with more than 40,000 deaths expected in the U.S. alone in 1996. Even with
FIELD OF THE INVENTION
The invention relates to the identification and use of gene expression profiles, or patterns, with clinical relevance to the treatment of breast cancer using tamoxifen (nolvadex) and other "antiestrogen" agents against breast cancer, including other "selective estrogen
FIELD OF THE INVENTION
Disclosed herein are methods for treating breast cancer comprising predicting or assessing the efficacy of a therapeutic regimen for breast cancer and administering an effective amount of a therapeutic agent to treat breast cancer in subjects. Specifically, disclosed are
FIELD OF THE INVENTION
The present invention relates generally to the field of adjuvant methods and devices for breast cancer treatment. Specifically, brachytherapy methods to treat a tumor, preferably a breast tumor, are described.
BACKGROUND OF THE INVENTION
One method of treating breast cancer is
FIELD OF THE INVENTION
The present invention relates to a method for determining a treatment procedure for breast cancer, a method of predicting a clinical response to a breast cancer treatment, and a method for selecting an endocrine therapy agent in treating breast cancer. In general, methods of
TECHNICAL FIELD
The claimed methods relate to biomarkers of breast cancer and methods of use thereof.
BACKGROUND
Breast carcinomas represent a heterogeneous group of tumors at the clinical, histopathologic, and molecular levels (Cancer Genome Atlas Network, Nature 490:61-70, 2012). The diversity of
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is filed under the provisions of 35 U.S.C. .sctn.371 and claims the priority of International Patent Application No. PCT/EP2015/061641, filed on 27 May 2015 entitled "ANTITUMOR ACTIVITY OF MULTI-KINASE INHIBITORS IN TRIPLE NEGATIVE BREAST
FIELD OF THE INVENTION
This invention relates to (among other things) the field of cancer chemotherapy. More specifically, the invention involves the treatment of an individual suffering from a cancer such as breast cancer by administering to the individual a long-acting topoisomerase I inhibitor,
The present invention relates to the use of the functional ingredients inulin, oligofructose or their derivatives for the manufacture of functional food, functional feed, OTC and pharmaceutical compositions for the prevention of mammary carcinogenesis or treatment of breast cancer. The invention
BACKGROUND OF THE INVENTION
The invention provides methods and compositions comprising steroids or analogs, such as analogs of androst-5-ene-3.beta.,17.beta.-diol ("AED") or 1,3,5(10)-estratriene-17.alpha.-ethynyl-3.beta.,17.beta.-diol ("EED") for use as agents to modulate the biological activity of